![Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study - Xin Wu, Binglu Li, Chaoji Zheng, 2022 Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study - Xin Wu, Binglu Li, Chaoji Zheng, 2022](https://journals.sagepub.com/cms/10.1177/15330338221078435/asset/images/large/10.1177_15330338221078435-fig3.jpeg)
Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study - Xin Wu, Binglu Li, Chaoji Zheng, 2022
![A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-09949-5/MediaObjects/41598_2022_9949_Fig1_HTML.png)
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
![Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804919307488-gr1.jpg)
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect
![ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy](https://www.urotoday.com/images/com-doc-importer/103-asco-gu-2023/asco-gu-2023-formula-509-a-multicenter-randomized-trial-of-post-operative-salvage-radiotherapy-and-6-months-of-gnrh-agonist-with-or-without-abiraterone-acetate-prednisone-and-apalutamide-post-radical-prostatectomy/image-0.jpg)
ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy
![A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer - Annals of Oncology A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/80addcfc-5a3d-41a1-92be-1d7b6a968bbe/gr1.jpg)
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer - Annals of Oncology
![Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma | Journal for ImmunoTherapy of Cancer | Full Text Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma | Journal for ImmunoTherapy of Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40425-019-0672-3/MediaObjects/40425_2019_672_Fig3_HTML.png)
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma | Journal for ImmunoTherapy of Cancer | Full Text
![Disease-free survival curve (Kaplan Meier) associated with clusterin... | Download Scientific Diagram Disease-free survival curve (Kaplan Meier) associated with clusterin... | Download Scientific Diagram](https://www.researchgate.net/publication/322040749/figure/fig1/AS:575601590194176@1514245521822/Disease-free-survival-curve-Kaplan-Meier-associated-with-clusterin-immunostaining-low.png)
Disease-free survival curve (Kaplan Meier) associated with clusterin... | Download Scientific Diagram
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics | PLOS ONE
Methodology to standardize heterogeneous statistical data presentations for combining time-to-event oncologic outcomes | PLOS ONE
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig3_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/6f00f669-f048-4578-a489-bf14cf2f4811/gr3.jpg)